Abstract

Breast cancer is the most common malignancy in women and the second leading cause of cancer death in women. Triple negative breast cancer (TNBC) subtype is a breast cancer subset without ER (estrogen receptor), PR (progesterone receptor) and HER2 (human epidermal growth factor receptor 2) expression, limiting treatment options and presenting a poorer survival rate. Thus, we investigated whether histone deacetylation inhibitor (HDACi) could be used as potential anti-cancer therapy on breast cancer cells. In this study, we found TNBC and HER2-enriched breast cancers are extremely sensitive to Panobinostat, Belinostat of HDACi via experiments of cell viability assay, apoptotic marker identification and flow cytometry measurement. On the other hand, we developed a bioluminescence-based live cell non-invasive apoptosis detection sensor (NIADS) detection system to evaluate the quantitative and kinetic analyses of apoptotic cell death by HDAC treatment on breast cancer cells. In addition, the use of HDACi may also contribute a synergic anti-cancer effect with co-treatment of chemotherapeutic agent such as doxorubicin on TNBC cells (MDA-MB-231), but not in breast normal epithelia cells (MCF-10A), providing therapeutic benefits against breast tumor in the clinic.

Original languageEnglish
Article number452
JournalInternational Journal of Molecular Sciences
Volume19
Issue number2
DOIs
Publication statusPublished - Feb 2 2018

Fingerprint

apoptosis
Cell death
death
breast
Histones
inhibitors
Cell Death
cancer
Cells
Triple Negative Breast Neoplasms
Apoptosis
Breast Neoplasms
sensors
Sensors
Bioluminescence
Flow cytometry
Progesterone Receptors
Estrogen Receptors
Doxorubicin
Tumors

Keywords

  • HDACi
  • Live cell non-invasive apoptosis detection sensor (NIADS)
  • Triple negative breast cancer (TNBC)

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

The application of non-invasive apoptosis detection sensor (NIADS) on histone deacetylation inhibitor (HDACI)-induced breast cancer cell death. / Hsu, Kai Wen; Huang, Chien Yu; Tam, Ka Wai; Lin, Chun Yu; Huang, Li Chi; Lin, Ching Ling; Hsieh, Wen Shyang; Chi, Wei Ming; Chang, Yu Jia; Wei, Po Li; Chen, Shou Tung; Lee, Chia Hwa.

In: International Journal of Molecular Sciences, Vol. 19, No. 2, 452, 02.02.2018.

Research output: Contribution to journalArticle

@article{52b95fb99edc4b178beadb2c7cb25c72,
title = "The application of non-invasive apoptosis detection sensor (NIADS) on histone deacetylation inhibitor (HDACI)-induced breast cancer cell death",
abstract = "Breast cancer is the most common malignancy in women and the second leading cause of cancer death in women. Triple negative breast cancer (TNBC) subtype is a breast cancer subset without ER (estrogen receptor), PR (progesterone receptor) and HER2 (human epidermal growth factor receptor 2) expression, limiting treatment options and presenting a poorer survival rate. Thus, we investigated whether histone deacetylation inhibitor (HDACi) could be used as potential anti-cancer therapy on breast cancer cells. In this study, we found TNBC and HER2-enriched breast cancers are extremely sensitive to Panobinostat, Belinostat of HDACi via experiments of cell viability assay, apoptotic marker identification and flow cytometry measurement. On the other hand, we developed a bioluminescence-based live cell non-invasive apoptosis detection sensor (NIADS) detection system to evaluate the quantitative and kinetic analyses of apoptotic cell death by HDAC treatment on breast cancer cells. In addition, the use of HDACi may also contribute a synergic anti-cancer effect with co-treatment of chemotherapeutic agent such as doxorubicin on TNBC cells (MDA-MB-231), but not in breast normal epithelia cells (MCF-10A), providing therapeutic benefits against breast tumor in the clinic.",
keywords = "HDACi, Live cell non-invasive apoptosis detection sensor (NIADS), Triple negative breast cancer (TNBC)",
author = "Hsu, {Kai Wen} and Huang, {Chien Yu} and Tam, {Ka Wai} and Lin, {Chun Yu} and Huang, {Li Chi} and Lin, {Ching Ling} and Hsieh, {Wen Shyang} and Chi, {Wei Ming} and Chang, {Yu Jia} and Wei, {Po Li} and Chen, {Shou Tung} and Lee, {Chia Hwa}",
year = "2018",
month = "2",
day = "2",
doi = "10.3390/ijms19020452",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "2",

}

TY - JOUR

T1 - The application of non-invasive apoptosis detection sensor (NIADS) on histone deacetylation inhibitor (HDACI)-induced breast cancer cell death

AU - Hsu, Kai Wen

AU - Huang, Chien Yu

AU - Tam, Ka Wai

AU - Lin, Chun Yu

AU - Huang, Li Chi

AU - Lin, Ching Ling

AU - Hsieh, Wen Shyang

AU - Chi, Wei Ming

AU - Chang, Yu Jia

AU - Wei, Po Li

AU - Chen, Shou Tung

AU - Lee, Chia Hwa

PY - 2018/2/2

Y1 - 2018/2/2

N2 - Breast cancer is the most common malignancy in women and the second leading cause of cancer death in women. Triple negative breast cancer (TNBC) subtype is a breast cancer subset without ER (estrogen receptor), PR (progesterone receptor) and HER2 (human epidermal growth factor receptor 2) expression, limiting treatment options and presenting a poorer survival rate. Thus, we investigated whether histone deacetylation inhibitor (HDACi) could be used as potential anti-cancer therapy on breast cancer cells. In this study, we found TNBC and HER2-enriched breast cancers are extremely sensitive to Panobinostat, Belinostat of HDACi via experiments of cell viability assay, apoptotic marker identification and flow cytometry measurement. On the other hand, we developed a bioluminescence-based live cell non-invasive apoptosis detection sensor (NIADS) detection system to evaluate the quantitative and kinetic analyses of apoptotic cell death by HDAC treatment on breast cancer cells. In addition, the use of HDACi may also contribute a synergic anti-cancer effect with co-treatment of chemotherapeutic agent such as doxorubicin on TNBC cells (MDA-MB-231), but not in breast normal epithelia cells (MCF-10A), providing therapeutic benefits against breast tumor in the clinic.

AB - Breast cancer is the most common malignancy in women and the second leading cause of cancer death in women. Triple negative breast cancer (TNBC) subtype is a breast cancer subset without ER (estrogen receptor), PR (progesterone receptor) and HER2 (human epidermal growth factor receptor 2) expression, limiting treatment options and presenting a poorer survival rate. Thus, we investigated whether histone deacetylation inhibitor (HDACi) could be used as potential anti-cancer therapy on breast cancer cells. In this study, we found TNBC and HER2-enriched breast cancers are extremely sensitive to Panobinostat, Belinostat of HDACi via experiments of cell viability assay, apoptotic marker identification and flow cytometry measurement. On the other hand, we developed a bioluminescence-based live cell non-invasive apoptosis detection sensor (NIADS) detection system to evaluate the quantitative and kinetic analyses of apoptotic cell death by HDAC treatment on breast cancer cells. In addition, the use of HDACi may also contribute a synergic anti-cancer effect with co-treatment of chemotherapeutic agent such as doxorubicin on TNBC cells (MDA-MB-231), but not in breast normal epithelia cells (MCF-10A), providing therapeutic benefits against breast tumor in the clinic.

KW - HDACi

KW - Live cell non-invasive apoptosis detection sensor (NIADS)

KW - Triple negative breast cancer (TNBC)

UR - http://www.scopus.com/inward/record.url?scp=85041490505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041490505&partnerID=8YFLogxK

U2 - 10.3390/ijms19020452

DO - 10.3390/ijms19020452

M3 - Article

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 2

M1 - 452

ER -